We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Drug Development in Microgravity Research Conducted Aboard Atlantis' Last Mission

By LabMedica International staff writers
Posted on 23 Jun 2010
Space Shuttle Atlantis returned from the International Space Station (ISS), landing at the Kennedy Space Center (Houston, TX, USA) May 26, 2010, with the 10th scientific payload for a commercial biotech company conducting drug development research.

Astrogenetix (Austin, TX, USA), is conducting research on methicillin-resistant Staphylococcus aureus (MRSA) as part of the ISS [U.S.] National Laboratory Pathfinder Vaccine (NLP-V) missions. More...
"By removing a force as fundamental as gravity in the course of this research, we're witnessing bacteria grow in ways that have not been demonstrated on Earth,” said John Porter, chief executive officer of Astrogenetix. "The use of microgravity as a new research platform will bring meaningful advancements in drug discovery and development, and we believe this early vaccine work is just the beginning.”

The company is utilizing the unique conditions of microgravity to reveal changes in bacteria, which can be targeted to create new vaccines and therapeutics. Astrogenetix has identified target genes for MRSA virulence by growing the bacteria in the microgravity environment during previous NLP-V. The company is conducting controls on this flight to validate earlier research by sending up several different strains of the bacteria, which were genetically modified to remove target genes that are believed to be associated with virulence of this organism. Moreover, the company is bringing back live forms of the bacteria that were grown in microgravity to compare to ground-based samples of the bacteria. The scientists will perform postflight analysis on the microbes to evaluate the changes that occurred on this mission.

"Each flight opportunity allows us to learn more about the bacteria and the changes that are occurring as they grow in space,” added Dr. Jeanne Becker, chief science officer for Astrogenetix. "The knowledge we're gaining can be applied to streamline and accelerate the development of vaccines and therapeutics on Earth.”

MRSA is a type of bacteria that is not responsive to commonly used antibiotics. In the United States alone, MRSA is responsible for 100,000 cases of severe infections and more than 19,000 deaths yearly. In the past 10 years, infection and mortality due to this organism has increased significantly, exceeding the death rate for HIV.

A subsidiary of Astrotech Corp., Astrogenetix, Inc. is a biotechnology company formed to commercialize biotechnology products processed in the unique environment of microgravity.

Related Links:

Autogenetix
International Space Station National Laboratory Pathfinder Vaccine



New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Gold Member
Hematology Analyzer
Medonic M32B
New
Laboratory Software
ArtelWare
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Platelets sequester cfDNA during circulation (Murphy L. et al., Science, 2025; DOI: 10.1126/science.adp3971)

Platelets Could Improve Early and Minimally Invasive Detection of Cancer

Platelets are widely recognized for their role in blood clotting and scab formation, but they also play a crucial role in immune defense by detecting pathogens and recruiting immune cells.... Read more

Immunology

view channel
Image: The test could streamline clinical decision-making by identifying ideal candidates for immunotherapy upfront (Xiao, Y. et al. Cancer Biology & Medicine July 2025, 20250038)

Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, making immunotherapy a promising yet unpredictable option. Current biomarkers such as PD-L1 expression or tumor... Read more

Microbiology

view channel
Image: New diagnostics could predict a woman’s risk of a common sexually transmitted infection (Photo courtesy of 123RF)

New Markers Could Predict Risk of Severe Chlamydia Infection

Chlamydia trachomatis is a common sexually transmitted infection that can cause pelvic inflammatory disease, infertility, and other reproductive complications when it spreads to the upper genital tract.... Read more

Pathology

view channel
image: Researchers Marco Gustav (right) and MD Nic G. Reitsam (left) discuss the study data (Photo courtesy of Anja Stübner/EKFZ)

AI Model Simultaneously Detects Multiple Genetic Colorectal Cancer Markers in Tissue Samples

Colorectal cancer is a complex disease influenced by multiple genetic alterations. Traditionally, studies and diagnostic tools have focused on predicting only one mutation at a time, overlooking the interplay... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.